

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 11 November 2025

Ref: 31035

Requested Information:

Regarding the incidence and treatment of endometrial cancer. I would greatly appreciate if you could answer the following questions.

Q1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli)
- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other Chemotherapy
- Durvalumab with platinum-based chemotherapy
- Pembrolizumab with platinum-based chemotherapy

Q2. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Q3. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) AND Chemotherapy
- Durvalumab with platinum-based chemotherapy
- Pembrolizumab with platinum-based chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other chemotherapy

Q4. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Response

Q1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli) **2**
- Dostarlimab (Jemperli) AND Chemotherapy **0**
- Hormone therapy (Progesterone or Letrozole) **4**
- Pembrolizumab (Keytruda) monotherapy **0**
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda) **3**
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) **10**
- Any other SACT **2**
- Any other Chemotherapy **0**
- Durvalumab with platinum-based chemotherapy **0**
- Pembrolizumab with platinum-based chemotherapy **0**

Q2. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?
6

Q3. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) AND Chemotherapy **0**
- Durvalumab with platinum-based chemotherapy **0**
- Pembrolizumab with platinum-based chemotherapy **0**
- Hormone therapy (Progesterone or Letrozole) **4**
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) **10**
- Any other SACT **0**
- Any other chemotherapy **0**

Q4. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Study Short Title	Study Full Title	Active Participants
BNT323-01	A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator's choice of chemotherapy in previously treated patients with HER2 expressing recurrent endometrial cancer.	Open No Recruitment
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (ENGOT-en23/GOG3095).	Open 1 in Follow Up
DOMENICA	DOMENICA (GINECO-EN105b/ENGOT-en13 study) Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting.	Closed to recruitment (no follow up) No Recruitment
RaNGO	Rare Neoplasms of Gynaecological Origin (RaNGO), is a study of specified rare gynaecological cancers to facilitate in-depth analysis of their clinical and biological behaviours leading to a greater understanding of mechanisms of disease progression and response to treatment, possibly also applicable to common tumours (including endometrial stromal sarcomas).	Closed to recruitment (in follow up) 23 In Follow Up
RUBY	A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)	Closed to recruitment (in follow up) No Active Participants

Additional Commentary

With reference to the clinical trial question (Q4), the data included relates to any clinical trials for the treatment of treatment of endometrial cancer which are currently recruiting participants or have participants under treatment or in follow-up.

The number of active participants relates to those participants currently undergoing treatment or in follow-up.

We have also listed active clinical trials at RCHT that do not have any active participants.

Attachment(s)

No attachment(s)

Date Response sent: 25 November 2025